神经肌肉病患者功能评定的临床应用进展

doi:10.3969/j.issn.1006-9771.2020.08.010

摘要/Abstract

摘要：

大部分神经肌肉病属于罕见病,其中相对较为常见的是Duchenne型肌营养不良和脊髓性肌萎缩症。神经肌肉病的一个重要特征是进行性残疾,因此功能评定对评价神经肌肉病患者的疾病严重程度、运动功能以及活动能力非常重要。目前功能评定包括肌力、关节活动度、姿势、活动能力等方面,涉及多种评定工具,但尚未形成统一标准。精确、合理的评定方法对多学科管理团队为患者制定个体化治疗方案具有重要意义。

关键词: 神经肌肉病, 罕见病, 运动功能评估, 综述

Abstract:

Most of the neuromuscular diseases are rare diseases, and Duchenne muscular dystrophy and Spinal muscular atrophy are common types of neuromuscular diseases. An important feature of neuromyopathy is progressive disability. Therefore, functional assessment is very important to evaluate the severity, motor function and activities of patients with neuromuscular disease. At present, the functional assessment invoved muscle strength, range of motion, posture and activities, and applied various functional assessment tools. However, there is no unified standard yet. Accurate and reasonable evaluation is essential for multidisciplinary management team to develop individualized treatment plan for patients.

Key words: neuromyopathy, rare diseases, motor function assessment, review

中图分类号:

R746

杨安琪,李文竹,黄真. 神经肌肉病患者功能评定的临床应用进展[J]. 《中国康复理论与实践》, 2020, 26(8): 923-929.

YANG An-qi,LI Wen-zhu,HUANG Zhen. Advance in Clinical Functional Assessment of Neuromuscular Disease (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2020, 26(8): 923-929.

参考文献 72

[1]	Phillips M, Flemming N, Tsintzas K. An exploratory study of physical activity and perceived barriers to exercise in ambulant people with neuromuscular disease compared with unaffected controls[J]. Clin Rehabil, 2009, 23(8):746-755. doi: 10.1177/0269215509334838
[2]	医政医管局. 国家卫生计生委办公厅关于成立国家卫生计生委罕见病诊疗与保障专家委员会的通知:国卫办医函〔2015〕1163号[EB/OL]. ( 2016- 01- 04). http://www.nhc.gov.cn/yzygj/s7659/201601/c918591a06154c1ea193fc32ba93c085.shtml.
[3]	医政医管局. 关于公布第一批罕见病目录的通知:国卫医发〔2018〕10号[EB/OL]. ( 2018- 06- 08). http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
[4]	中华人民共和国国家卫生健康委员会. 李克强主持召开国务院常务会议听取2018年全国两会建议提案办理工作汇报等[EB/OL]. ( 2019- 02- 11). http://www.nhc.gov.cn/wjw/xwdt/201902/139b69d4e19b4c35a00de020d194b9cf.shtml.
[5]	Ke Q, Zhao Z Y, Griggs R, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment[J]. World J Pediatr, 2017, 13(3): 197-201. doi: 10.1007/s12519-017-0036-3
[6]	北京医学会罕见病分会, 北京医学会神经内科分会神经肌肉病学组, 中国肌营养不良协作组. Duchenne型肌营养不良多学科管理专家共识[J]. 中华医学杂志, 2018, 98(35):2803-2814.
	Rare Diseases Branch of Beijing Medical Association, Neuromusculopathy Group of Neurology Branch of Beijing Medical Association, Chinese Muscular Dystrophy Cooperative Group. Expert Consensus of Duchenne Muscular Dystrophy Multidisciplinary Management[J]. Natl Med J Chin, 2018, 98(35):2803-2814.
[7]	李宁, 沈定国. 进行性脊髓性肌萎缩症的基因诊断研究[J]. 中华神经科杂志, 1998, 31(6):25-27.
	Li N, Shen D G. Genetic diagnosis of progressive spinal muscular atrophy[J]. Chin J Neurol, 1998, 31(6):25-27.
[8]	Feng Y, Ge X, Meng L, et al. The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing[J]. Genet Med, 2017, 19(8): 936-944. doi: 10.1038/gim.2016.215
[9]	李晓光, 郭玉璞, 刘天慈. 脊髓性肌萎缩症临床与肌肉病理学研究[J]. 中华神经科杂志, 2000, 33(1):32-35.
	Li X G, Guo Y P, Liu T C. Clinical and pathological investigation of spinal muscular atrophy[J]. Chin J Neurol, 2000, 33(1):32-35.
[10]	宋昉. 近端脊髓性肌萎缩症的临床分型和基因诊断[J]. 实用儿科临床杂志, 2012, 27(8):9-11.
	Song F. Clinical classification and genetic diagnosis of proximal spinal muscular atrophy[J]. Chin J Appl Clin Pediatr, 2012, 27(8):9-11.
[11]	北京医学会罕见病分会, 北京医学会医学遗传学分会, 北京医学会神经病学分会神经肌肉病学组, 等. 脊髓性肌萎缩症多学科管理专家共识[J]. 中华医学杂志, 2019, 99(19):1460-1467.
	Rare Diseases Branch of Beijing Medical Association, Medical Genetics Branch of Beijing Medical Association, Neuromusculopathy Group of Neurology Branch of Beijing Medical Association, et al. Multidisciplinary Expert Consensus on the Management of Spinal Muscular Atrophy[J]. Natl Med J Chin, 2019, 99(19):1460-1467.
[12]	Birnkrant D J, Bushby K, Bann C M, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management[J]. Lancet Neurol, 2018, 17(3): 251-267. doi: S1474-4422(18)30024-3 pmid: 29395989
[13]	Bushby K, Finkel R, Birnkrant D J, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care[J]. Lancet Neurol, 2010, 9(2): 177-189. doi: 10.1016/S1474-4422(09)70272-8
[14]	Carter J C, Sheehan D W, Prochoroff A, et al. Muscular dystrophies[J]. Clin Chest Med, 2018, 39(2):377-389. doi: S0272-5231(18)30004-2 pmid: 29779596
[15]	Abresch R T, Carter G T, Han J J, et al. Exercise in neuromuscular diseases[J]. Phys Med Rehabil Clin N Am, 2012, 23(3): 653-673. doi: 10.1016/j.pmr.2012.06.001
[16]	Florence J M, Shree P, King W M, et al. Intrarater reliability of Manual Muscle Test (Medical Research Council Scale) Grades in Duchenne's muscular dystrophy[J]. Phys Ther, 1992, 72(2): 115-126. pmid: 1549632
[17]	Mayhew J E, Florence J M, Mayhew T P, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy[J]. Muscle Nerve, 2007, 35(1): 36-42. pmid: 16969838
[18]	Werlauff U, Steffensen B F. The applicability of four clinical methods to evaluate arm and hand function in all stages of spinal muscular atrophy type II[J]. Disabil Rehabil, 2014, 36(25): 2120-2126. doi: 10.3109/09638288.2014.892157 pmid: 24579651
[19]	史惟, 李惠, 苏怡, 等. 定量等长肌力测定在Duchenne型和Becker型肌营养不良症患儿下肢肌力测定中的信度评价[J]. 中国现代神经疾病杂志, 2015, 15(5):57-62.
	Shi W, Li H, Su Y, et al. Reliability of hand-held dynamometry for measurement of lower limb muscle strength in children with Duchenne and Becker type muscular dystrophy[J]. Chin J Contemp Neurol Neurosurg, 2015, 15(5):57-62.
[20]	Bulut N, Gürbüz I, Yilmaz Z, et al. The association of hand grip strength with functional measures in non-ambulatory children with Duchenne muscular dystrophy[J]. Arq Neuropsiquiatr, 2019, 77(11): 792-796. doi: 10.1590/0004-282x20190161
[21]	Zaidman C M, Wang L L, Connolly A M, et al. Electrical impedance myography in Duchenne muscular dystrophy and healthy controls: a multicenter study of reliability and validity[J]. Muscle Nerve, 2015, 52(4):592-597. doi: 10.1002/mus.24611 pmid: 25702806
[22]	Mcdonald C M, Abresch R T, Carter G T, et al. Profiles of neuromuscular diseases. Becker's muscular dystrophy[J]. Am J Phys Med Rehabil, 1995, 74(5 Suppl): S93-S103.
[23]	Fujak A, Kopschina C, Gras F, et al. Contractures of the lower extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection[J]. Ortop Traumatol Rehabil, 2011, 13(1): 27-36. doi: 10.5604/15093492.933792
[24]	Carter G T, Abresch R T, Fowler W M, et al. Profiles of neuromuscular diseases. Spinal muscular atrophy[J]. Am J Phys Med Rehabil, 1995, 74(5 Suppl): S150-S159.
[25]	Sá C D, Fagundes I K, Araújo T B, et al. The relevance of trunk evaluation in Duchenne muscular dystrophy: the Segmental Assessment of Trunk Control[J]. Arq Neuropsiquiatr, 2016, 74(10):791-795. doi: 10.1590/0004-282X20160124
[26]	Stępień A, Jędrzejowska M, Guzek K, et al. Reliability of four tests to assess body posture and the range of selected movements in individuals with spinal muscular atrophy[J]. BMC Musculoskelet Disord, 2019, 20(1):54. doi: 10.1186/s12891-018-2389-8
[27]	McDonald C M, Henricson E K, Abresch R T, et al. The 6-minute Walk Test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study[J]. Muscle Nerve, 2013, 48(3):343-356. doi: 10.1002/mus.23902 pmid: 23681930
[28]	Young S D, Montes J, Kramer S S, et al. Six-Minute Walk Test is reliable and valid in spinal muscular atrophy[J]. Muscle Nerve, 2016, 54(5): 836-842. doi: 10.1002/mus.25120
[29]	Geiger R, Strasak A, Treml B, et al. Six-Minute Walk Test in children and adolescents[J]. J Pediatr, 2007, 150(4): 395-399, 399.e1-2.
[30]	Dunaway S, Montes J, Garber C E, et al. Performance of the Timed "Up & Go" Test in spinal muscular atrophy[J]. Muscle Nerve, 2014, 50(2): 273-277. doi: 10.1002/mus.24153 pmid: 24375426
[31]	Meilleur K G, Jain M S, Hynan L S, et al. Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies[J]. Neuromuscul Disord, 2015, 25(1): 43-54. doi: 10.1016/j.nmd.2014.09.010
[32]	Awano H, Itoh C, Takeshima Y, et al. Ambulatory capacity in Japanese patients with Duchenne muscular dystrophy[J]. Brain Dev, 2018, 40(6): 465-472. doi: 10.1016/j.braindev.2018.02.011
[33]	Montes J, Zanotto D, Dunaway Young S, et al. Gait assessment with solesound instrumented footwear in spinal muscular atrophy[J]. Muscle Nerve, 2017, 56(2): 230-236. doi: 10.1002/mus.v56.2
[34]	Mazzone E S, Coratti G, Sormani M P, et al. Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: an observational study[J]. PLoS One, 2016, 11(3):e0151445. doi: 10.1371/journal.pone.0151445
[35]	张昊, 周宁, 吴士文. Duchenne型肌营养不良患者运动功能分析[J]. 中国康复理论与实践, 2018, 24(2):214-218.
	Zhang H, Zhou N, Wu S W. Analysis of motor function in patients with Duchenne muscular dystrophy[J]. Chin J Rehabil Theory Pract, 2018, 24(2):214-218.
[36]	Yuko S M, Terumi M, En K, et al. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis[J]. Orphanet J Rare Dis, 2018, 13(1):93. doi: 10.1186/s13023-018-0834-2
[37]	Sienkiewicz D, Kułak W, Okurowska-Zawada B, et al. Efficacy and the safety of granulocyte colony-stimulating factor treatment in patients with muscular dystrophy: a non-randomized clinical trial[J]. Front Neurol, 2017, 8:566. doi: 10.3389/fneur.2017.00566 pmid: 29123500
[38]	Arora H, Willcocks R J, Lott D J, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: Imaging DMD cohort natural history[J]. Muscle Nerve, 2018, 58(5): 631-638. doi: 10.1002/mus.26161
[39]	Lennie J L, Mondick J T, Gastonguay M R. Latent process model of the 6-minute Walk Test in Duchenne muscular dystrophy[J]. J Pharmacokinet Pharmacodyn, 2020, 47(1): 91-104. doi: 10.1007/s10928-020-09671-7
[40]	Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute Walk Test and timed items in ambulant boys with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2010, 20(11): 712-716. doi: 10.1016/j.nmd.2010.06.014
[41]	Jacqueline M, Mcdermott M P, Elizabeth M, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression[J]. PLoS One, 2018, 13(6):e0199657. doi: 10.1371/journal.pone.0199657
[42]	Pera M C, Luigetti M, Pane M, et al. 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction[J]. Neuromuscul Disord, 2017, 27(10): 879-882. doi: 10.1016/j.nmd.2017.07.007
[43]	Komaki H, Maegaki Y, Matsumura T, et al. Early phase 2 trial of TAS5 in patients with Duchenne muscular dystrophy[J]. Ann Clin Transl Neurol, 2020, 7(2): 181-190. doi: 10.1002/acn3.v7.2
[44]	Darras B T, Chiriboga C A, Iannaccone S T, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies[J]. Neurology, 2019, 92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527
[45]	Mazzone E S, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting[J]. Neuromuscul Disord, 2009, 19(7): 458-461. doi: 10.1016/j.nmd.2009.06.368
[46]	McDonald C M, Campbell C, Torricelli R E, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10101): 1489-1498. doi: S0140-6736(17)31611-2 pmid: 28728956
[47]	Mercuri E, Mayhew A, Muntoni F, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th-13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June-1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France[J]. Neuromuscul Disord, 2008, 18(11): 894-903. doi: 10.1016/j.nmd.2008.07.003
[48]	Ricotti V, Ridout D A, Pane M, et al. The North Star Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials[J]. J Neurol Neurosurg Psychiatry, 2016, 87(2): 149-155.
[49]	Mercuri E, Signorovitch J E, Swallow E, et al. Categorizing natural history trajectories of ambulatory function measured by the 6-minute Walk Distance in patients with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2016, 26(9): 576-583. doi: 10.1016/j.nmd.2016.05.016
[50]	Lattre C D, Payan C, Vuillerot C, et al. Motor Function Measure: validation of a short form for young children with neuromuscular diseases[J]. Arch Phys Med Rehabil, 2013, 94(11): 2218-2226. doi: 10.1016/j.apmr.2013.04.001
[51]	Huang M, Cao J, Sun J, et al. Cross-cultural adaptation and multi-centric validation of the Motor Function Measure Chinese Version (MFM-32-CN) for patients with neuromuscular diseases[J]. Dev Neurorehabil, 2020, 23(4): 210-217. doi: 10.1080/17518423.2019.1642413
[52]	Bérard C, Payan C, Hodgkinson I, et al. A motor function measure for neuromuscular diseases. Construction and validation study[J]. Neuromuscul Disord, 2005, 15(7): 463-470. doi: 10.1016/j.nmd.2005.03.004
[53]	Vuillerot C, Girardot F, Payan C, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure[J]. Dev Med Child Neurol, 2010, 52(1):60-65. doi: 10.1111/j.1469-8749.2009.03316.x pmid: 19453691
[54]	Jansen M, Van Alfen N, Geurts A C H, et al. Assisted bicycle training delays functional deterioration in boys with Duchenne muscular dystrophy: the randomized controlled trial "no use is disuse"[J]. Neurorehabil Neural Repair, 2013, 27(9): 816-827. doi: 10.1177/1545968313496326 pmid: 23884013
[55]	Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind,placebo-controlled phase 2 trial[J]. Lancet Neurol, 2017, 16(7): 513-522. doi: S1474-4422(17)30085-6 pmid: 28460889
[56]	Main M, Kairon H, Mercuri E, et al. The Hammersmith Functional Motor Scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation[J]. Paediatr Neurol, 2003, 7(4): 155-159.
[57]	O'Hagen J M, Glanzman A M, McDermott M P, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients[J]. Neuromuscul Disord, 2007, 17(9-10): 693-697. doi: 10.1016/j.nmd.2007.05.009
[58]	Glanzman A M, O'Hagen J M, McDermott M P, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy Type II and III[J]. J Child Neurol, 2011, 26(12): 1499-1507. doi: 10.1177/0883073811420294 pmid: 21940700
[59]	Bartels B, Montes J, van der Pol W L, et al. Physical exercise training for type 3 spinal muscular atrophy[J]. Cochrane Database Syst Rev, 2019, 3(3): CD012120.
[60]	Wadman R I, Wijngaarde C A, Stam M, et al. Muscle strength and motor function throughout life in a cross- sectional cohort of 180 patients with SMA types 1c-4[J]. Eur J Neurol, 2018, 25(3): 512-518. doi: 10.1111/ene.13534 pmid: 29194869
[61]	Glanzman A M, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability[J]. Neuromuscul Disord, 2010, 20(3): 155-161. doi: 10.1016/j.nmd.2009.11.014
[62]	Pechmann A, Langer T, Schorling D, et al. Evaluation of children with SMA type 1 under treatment with Nusinersen within the Expanded Access Program in Germany[J]. J Neuromuscul Dis, 2018, 5(2): 135-143. doi: 10.3233/JND-180315 pmid: 29689734
[63]	Kolb S J, Coffey C S, Yankey J W, et al. Natural history of infantile-onset spinal muscular atrophy[J]. Ann Neurol, 2017, 82(6): 883-891. doi: 10.1002/ana.v82.6
[64]	Finkel R S, Mcdermott M P, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials[J]. Neurology, 2014, 83(9): 810-817. doi: 10.1212/WNL.0000000000000741
[65]	Olsson B, Alberg L, Cullen N C, et al. NFL is a marker of treatment response in children with SMA treated with nusinersen[J]. J Neurol, 2019, 266(9): 2129-2136. doi: 10.1007/s00415-019-09389-8 pmid: 31123861
[66]	Steffensen B, Hyde S, Lyager S, et al. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy[J]. Physiother Res Int, 2001, 6(3): 119-134. doi: 10.1002/(ISSN)1471-2865
[67]	Fagoaga J, Girabent-Farres M, Bagur-Calafat C. [Evolution of functional capacity, assessed with the Egen Klassifikation scale, in the Spanish population with spinal muscular atrophy or Duchenne muscular dystrophy. A three year longitudinal study][J]. [in Spanish]. Rev Neurol, 2015, 61(8):344-348.
[68]	Alemdaroğlu İ, Karaduman A, İyigün-Yatar G, et al. Turkish version of the Egen Klassifikation Scale version 2: Validity and reliability in the Turkish population[J]. Turk J Pediatr, 2014, 56(6): 643-650.
[69]	Fagoaga J, Girabent-Farrés M, Bagur-Calafat C, et al. Functional assessment for people unable to walk due to spinal muscular atrophy and Duchenne muscular dystrophy. Translation and validation of the Egen Klassifikation 2 scale for the Spanish population[J]. Rev Neurol, 2015, 60(10): 439-446.
[70]	Vignos P J, Spencer G E, Archibald K C. Management of progressive muscular dystrophy in children[J]. JAMA, 1963, 184(2):89-96.
[71]	Brooke M H, Griggs R C, Mendell J R, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol[J]. Muscle Nerve, 1981, 4(3): 186-197. pmid: 7017401
[72]	Jung I Y, Chae J H, Park S K, et al. The correlation analysis of functional factors and age with Duchenne muscular dystrophy[J]. Ann Rehabil Med, 2012, 36(1): 22-32. doi: 10.5535/arm.2012.36.1.22